

This material is for healthcare professionals in Ireland only.
Weight-based dosing is applicable for the first RSV season only.

<5 kg weight | 1 x 50 mg dose¹

Beyfortus ▼
(nirsevimab)

Beyfortus[®] is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:¹

- i. Neonates and infants during their first RSV season
- ii. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season

Beyfortus[®] should be used in accordance with official recommendations.¹

Administration quick tips



Double check the injection site

Beyfortus[®] is for intramuscular injection **only**, preferably given in the **anterolateral aspect of the thigh**.^{*1}



Co-administration

When applicable, Beyfortus[®] can be given concomitantly with childhood vaccines.^{**1}

See the Summary of Product Characteristics for full dosing and administration information.

* The gluteal muscle should not be used routinely as an injection site, due to the risk of damage to the sciatic nerve.¹

** Beyfortus[®] should not be mixed with any vaccine in the same syringe or vial. When administered concomitantly with injectable vaccines, they should be given with separate syringes and at different injection sites.¹

RSV, respiratory syncytial virus.

1. Beyfortus[®] (nirsevimab) IE Summary of Product Characteristics (SmPC), September 2024.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie; email: medsafety@hpra.ie. Adverse events should also be reported to Sanofi Ireland Ltd. Tel: 01 403 5600. Alternatively, send via email to IEPharmacovigilance@sanofi.com.

This material is for healthcare professionals in Ireland only.
Weight-based dosing is applicable for the first RSV season only.

≥5 kg weight | 1 x 100 mg dose¹

Beyfortus ▼
(nirsevimab)

For children vulnerable to severe RSV disease through their second season, regardless of weight

1 x 200 mg given as 2 x 100 mg injections¹

Beyfortus[®] is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:¹

- i. Neonates and infants during their first RSV season
 - ii. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season
- Beyfortus[®] should be used in accordance with official recommendations.¹

Administration quick tips



Double check the injection site

Beyfortus[®] is for intramuscular injection **only**, preferably given in the **anterolateral aspect of the thigh**.^{*1} If two injections are required, different injection sites should be used.¹



Co-administration

When applicable, Beyfortus[®] can be given concomitantly with childhood vaccines.^{**1}

See the Summary of Product Characteristics for full dosing and administration information.

* The gluteal muscle should not be used routinely as an injection site, due to the risk of damage to the sciatic nerve.¹

** Beyfortus[®] should not be mixed with any vaccine in the same syringe or vial. When administered concomitantly with injectable vaccines, they should be given with separate syringes and at different injection sites.¹

RSV, respiratory syncytial virus.

1. Beyfortus[®] (nirsevimab) IE Summary of Product Characteristics (SmPC), September 2024.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie; email: medsafety@hpra.ie. Adverse events should also be reported to Sanofi Ireland Ltd. Tel: 01 403 5600. Alternatively, send via email to JEPHarmacovigilance@sanofi.com.

